Full Press Release Details
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for
chronic spontaneous urticaria
Paris and Tarrytown, NY, November 25,
2025. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent
patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naive to anti- immunoglobulin-E (IgE) therapy for CSU. Eligible
patients can use Dupixent as a first-line targeted treatment option.
"The unpredictable nature of chronic spontaneous urticaria leaves
patients guessing when they'll have their next outbreak of disruptive, debilitating hives and itch, which can make life challenging," said Tonya Winders, President & CEO, Global Allergy & Airways Patient
Platform. "Dupixent is proven to reduce these intense symptoms and has the potential to make a positive impact on people struggling to control this disease."
"Standard-of-care, first-line treatment options like
antihistamines offer limited relief for many people living with uncontrolled chronic spontaneous urticaria, leaving them to face unrelenting cycles of itch and hives," said Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head,
Immunology Development at Sanofi. "Dupixent significantly reduced these symptoms of CSU and led to more patients experiencing well-controlled disease or a complete response compared to placebo in two phase 3 studies. Now, eligible patients
with CSU in the EU have a new option that is proven to reduce itch and hives."
The approval is based on data from two phase 3 clinical
studies in the LIBERTY-CUPID program (NCT04180488). Study A and
Study C included 284 patients aged 12 years and older who were symptomatic despite the use of antihistamines and who were
na ve to anti-IgE therapy. Both studies assessed Dupixent as an add-on therapy to standard-of-care antihistamines compared
to antihistamines alone and demonstrated Dupixent significantly reduced urticaria activity (a composite of itch and hives), and individual measures of itch and hive severity compared to placebo at 24 weeks. Dupixent also increased the percentage of
patients with well-controlled disease and complete response at 24 weeks compared to placebo. Study B (n=108) provided additional
safety data and evaluated Dupixent in patients aged 12 years and older who were inadequate responders or intolerant to anti-IgE therapy and symptomatic despite antihistamine use.
Safety results from Study A, Study B and Study C were generally consistent with the known safety
profile of Dupixent in its approved indications. The most common adverse reactions for Dupixent overall are injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes, and eosinophilia. Additional adverse reactions of
injection site induration, injection site dermatitis, and injection site hematoma were reported in the CSU adult and adolescent studies. Adverse events more commonly observed with Dupixent ( 5%)
than placebo in patients with CSU were injection site reaction, COVID-19, hypertension, CSU, and accidental overdose.
"The approval of Dupixent for certain adults and adolescents with chronic spontaneous urticaria in the European Union
represents the first innovation for patients with this disease in over a decade," said George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer at Regeneron.
"Physicians now have a new approach for CSU with Dupixent, as the only treatment that inhibits IL4 and IL13, two key drivers of type 2 inflammation, and can offer patients significant improvement in debilitating itch and hives. This
approval further demonstrates the ability of Dupixent to advance the treatment landscape for yet another chronic type 2 inflammatory disease, with a well-established safety profile across its indications."
Beyond the EU, Dupixent is also approved for CSU in certain adults and adolescents in several countries including the US and Japan.
CSU is a chronic, inflammatory
skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. CSU is typically treated with H1AH, medicines that target H1 receptors on cells to control symptoms of itch and urticaria. However,
the disease remains uncontrolled despite H1AH treatment in many patients, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and significantly impact their
quality of life. More than 270,000 people in the EU aged 12 years and older suffer from CSU that is inadequately controlled by antihistamines.
About the Dupixent CSU phase 3 study program
The LIBERTY-CUPID phase 3 program evaluating Dupixent for CSU consists of Study
A, Study B, and Study C. These studies were randomized, double-blind, placebo-controlled clinical studies that evaluated the efficacy and safety of Dupixent
as an add-on therapy to standard-of-care antihistamines compared to antihistamines alone. Studies A and C were replicate studies
that assessed patients aged 6 years and older who remained symptomatic despite the use of antihistamines and were na ve to anti-IgE therapy. Study B was conducted in patients aged 12 years and older who were symptomatic despite use of
antihistamines and were inadequate responders or intolerant to anti-IgE therapy. During the 24-week treatment period in all three studies, all patients received an initial loading dose followed by either 300
mg Dupixent every two weeks, or 200 mg every two weeks for adolescents weighing <60 kg.
The primary endpoint in all three studies
assessed the change from baseline in itch and hives (weekly urticaria activity score [UAS7], 0-42 scale). The key secondary endpoint (also assessed at 24 weeks) was change from baseline in itch (measured by
the weekly itch severity score, 0-21 scale). Additional secondary endpoints assessed at 24 weeks evaluated:
The results from Studies A and B were published in The Journal of Allergy and Clinical Immunology.
Dupixent (dupilumab) is
an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with CSU who remain symptomatic despite H1AH treatment, Dupixent 300 mg is administered every two weeks after an initial loading dose. In
patients aged 12 to 17 years with CSU who remain symptomatic despite H1AH treatment, Dupixent is administered every two weeks based on weight (200 mg for adolescents 30 to <60 kg, 300 mg for
adolescents 60 kg) after an initial loading dose. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a
healthcare professional. In adolescents aged 12 to 17 years, Dupixent should be administered under the supervision of an adult.
fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent
development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple
related and often co-morbid diseases.
Dupixent has received regulatory approvals in more than 60
countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary
disease, and bullous pemphigoid in different age populations. More than 1.3 million patients are being treated with Dupixent globally.
Dupilumab development program
is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by
type 2 inflammation.
In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases
driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin, lichen simplex chronicus, and allergic fungal rhinosinusitis. These potential uses of dupilumab are currently under clinical
investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with
serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were
homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious
diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug
development using our proprietary technologies, such as VelociSuite , which produces optimized fully human antibodies and new classes of bispecific
antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to
identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn,
Instagram, Facebook or X.
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and
delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our
team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare,
environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 |
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
L o Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 |
L a Ubaldi | +33 6 30 19 66 46 |
Sanofi Investor Relations
Thomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com
Aliz Kaisserian | +33 6 47 04 12 11 |
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 |
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | +1 617 710 3587 |
Thibaud Ch telet | +33 6 80 80 89 90 |
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Regeneron Media Relations